Literature DB >> 27267556

Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference.

Mustafa Sahin1, Elizabeth P Henske2, Brendan D Manning3, Kevin C Ess4, John J Bissler5, Eric Klann6, David J Kwiatkowski2, Steven L Roberds7, Alcino J Silva8, Coryse St Hillaire-Clarke9, Lisa R Young10, Mark Zervas11, Laura A Mamounas12.   

Abstract

On March 10 to March 12, 2015, the National Institute of Neurological Disorders and Stroke and the Tuberous Sclerosis Alliance sponsored a workshop in Bethesda, Maryland, to assess progress and new opportunities for research in tuberous sclerosis complex with the goal of updating the 2003 Research Plan for Tuberous Sclerosis (http://www.ninds.nih.gov/about_ninds/plans/tscler_research_plan.htm). In addition to the National Institute of Neurological Disorders and Stroke and Tuberous Sclerosis Alliance, participants in the strategic planning effort and workshop included representatives from six other Institutes of the National Institutes of Health, the Department of Defense Tuberous Sclerosis Complex Research Program, and a broad cross-section of basic scientists and clinicians with expertise in tuberous sclerosis complex along with representatives from the pharmaceutical industry. Here we summarize the outcomes from the extensive premeeting deliberations and final workshop recommendations, including (1) progress in the field since publication of the initial 2003 research plan for tuberous sclerosis complex, (2) the key gaps, needs, and challenges that hinder progress in tuberous sclerosis complex research, and (3) a new set of research priorities along with specific recommendations for addressing the major challenges in each priority area. The new research plan is organized around both short-term and long-term goals with the expectation that progress toward specific objectives can be achieved within a five to ten year time frame.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27267556      PMCID: PMC4921275          DOI: 10.1016/j.pediatrneurol.2016.03.015

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  79 in total

1.  Why animal research needs to improve.

Authors:  Malcolm Macleod
Journal:  Nature       Date:  2011-09-28       Impact factor: 49.962

2.  Arp2/3 complex-deficient mouse fibroblasts are viable and have normal leading-edge actin structure and function.

Authors:  Alessia Di Nardo; Gregor Cicchetti; Hervé Falet; John H Hartwig; Thomas P Stossel; David J Kwiatkowski
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-27       Impact factor: 11.205

Review 3.  The neurology of mTOR.

Authors:  Jonathan O Lipton; Mustafa Sahin
Journal:  Neuron       Date:  2014-10-22       Impact factor: 17.173

4.  Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Nicholas R Rensing; Bo Zhang; David H Gutmann; Michael J Gambello; Michael Wong
Journal:  Hum Mol Genet       Date:  2010-11-09       Impact factor: 6.150

5.  Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features.

Authors:  Elizabeth Yuan; Peter T Tsai; Emily Greene-Colozzi; Mustafa Sahin; David J Kwiatkowski; Izabela A Malinowska
Journal:  Hum Mol Genet       Date:  2012-06-29       Impact factor: 6.150

6.  Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome.

Authors:  Suchithra Menon; Christian C Dibble; George Talbott; Gerta Hoxhaj; Alexander J Valvezan; Hidenori Takahashi; Lewis C Cantley; Brendan D Manning
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

7.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

Review 8.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.

Authors:  Jingxiang Huang; Brendan D Manning
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

Review 9.  Preclinical research in Rett syndrome: setting the foundation for translational success.

Authors:  David M Katz; Joanne E Berger-Sweeney; James H Eubanks; Monica J Justice; Jeffrey L Neul; Lucas Pozzo-Miller; Mary E Blue; Diana Christian; Jacqueline N Crawley; Maurizio Giustetto; Jacky Guy; C James Howell; Miriam Kron; Sacha B Nelson; Rodney C Samaco; Laura R Schaevitz; Coryse St Hillaire-Clarke; Juan L Young; Huda Y Zoghbi; Laura A Mamounas
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

10.  Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing.

Authors:  Magdalena E Tyburczy; Kira A Dies; Jennifer Glass; Susana Camposano; Yvonne Chekaluk; Aaron R Thorner; Ling Lin; Darcy Krueger; David N Franz; Elizabeth A Thiele; Mustafa Sahin; David J Kwiatkowski
Journal:  PLoS Genet       Date:  2015-11-05       Impact factor: 5.917

View more
  22 in total

Review 1.  Neuronal lysosomes.

Authors:  Shawn M Ferguson
Journal:  Neurosci Lett       Date:  2018-04-04       Impact factor: 3.046

2.  TSC1 Gene Therapy AAVerts Neurological Associated Mortality.

Authors:  David M Feliciano
Journal:  Mol Ther       Date:  2019-08-20       Impact factor: 11.454

3.  Inactivation of Tsc2 in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney.

Authors:  Leslie S Gewin; Megan E Summers; Julie W Harral; Christa F Gaskill; Stellor Nlandu Khodo; Surekha Neelisetty; Timothy M Sullivan; Katharina Hopp; J Jeffrey Reese; Dwight J Klemm; Valentina Kon; Kevin C Ess; Wei Shi; Susan M Majka
Journal:  Am J Physiol Renal Physiol       Date:  2019-08-28

4.  Predictors of Drug-Resistant Epilepsy in Tuberous Sclerosis Complex.

Authors:  Anna Jeong; Jo Anne Nakagawa; Michael Wong
Journal:  J Child Neurol       Date:  2017-12       Impact factor: 1.987

5.  Radiobiological Characterization of Tuberous Sclerosis: a Delay in the Nucleo-Shuttling of ATM May Be Responsible for Radiosensitivity.

Authors:  Mélanie L Ferlazzo; Mohamed Kheir Eddine Bach-Tobdji; Amar Djerad; Laurène Sonzogni; Clément Devic; Adeline Granzotto; Larry Bodgi; Jean-Thomas Bachelet; Assia Djefal-Kerrar; Christophe Hennequin; Nicolas Foray
Journal:  Mol Neurobiol       Date:  2017-08-07       Impact factor: 5.590

Review 6.  Neurogenetics in Child Neurology: Redefining a Discipline in the Twenty-first Century.

Authors:  Walter E Kaufmann
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

7.  Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.

Authors:  Avery J Zucco; Valentina Dal Pozzo; Alina Afinogenova; Ronald P Hart; Orrin Devinsky; Gabriella D'Arcangelo
Journal:  Mol Cell Neurosci       Date:  2018-08-23       Impact factor: 4.314

8.  Tuberous Sclerosis Complex: A Roadmap for Future Research.

Authors:  Anna Jeong
Journal:  Pediatr Neurol Briefs       Date:  2016-07

9.  Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants.

Authors:  Peter E Davis; Rajna Filip-Dhima; Georgios Sideridis; Jurriaan M Peters; Kit Sing Au; Hope Northrup; E Martina Bebin; Joyce Y Wu; Darcy Krueger; Mustafa Sahin
Journal:  Pediatrics       Date:  2017-11-03       Impact factor: 7.124

10.  Heterozygous loss of TSC2 alters p53 signaling and human stem cell reprogramming.

Authors:  Laura C Armstrong; Grant Westlake; John P Snow; Bryan Cawthon; Eric Armour; Aaron B Bowman; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2017-12-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.